Section
Clinical evidence, public health systems, and the economics of care. We read the trial data, weigh effect sizes against headlines, and track what actually reaches patients.
2 articles in this section
Registration was supposed to end selective publication. Two decades on, compliance with reporting requirements remains close to a coin flip, and enforcement is rare.
New antibiotics keep reaching approval and then bankrupting their developers. The problem is a business model that punishes exactly the drugs we most need held in reserve.
